NYSE Euronext Announces Trading Volumes for February 2013

Updated

NYSE Euronext Announces Trading Volumes for February 2013

Global Derivatives ADV Up 25% Y-o-Y Driven by Strong Fixed Income Trading, Up 71%

European Cash Equity ADV Up 13% M-o-M; U.S. Cash Equity ADV Up 1% M-o-M


U.S. Equity Options ADV Up 6% Y-o-Y

NEW YORK--(BUSINESS WIRE)-- NYSE Euronext (NYX) today announced trading volumes for its global derivatives and cash equities exchanges for February 20131. Global derivatives average daily volume ("ADV") of 8.8 million contracts in February 2013 increased 24.7% compared to February 2012, but decreased 7.6% month-over-month. This increase was primarily driven by stronger European derivatives volume, specifically fixed income derivatives ADV which increased 71% year-over-year. U.S. equity options ADV increased 5.7% compared to February 2012, but decreased 9.8% from January 2013 levels. Trading volumes in European cash equities were down 9.8% year-over-year, but rebounded up 12.8% month-over-month.

Highlights

  • NYSE Euronext global derivatives ADV in February 2013 of 8.8 million contracts increased 24.7% compared to February 2012, but decreased 7.6% from January 2013 levels.

  • NYSE Euronext European derivatives products ADV in February 2013 of 4.4 million contracts increased 54.4% compared to February 2012, but decreased 10.0% from January 2013 levels. Excluding Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives products ADV increased 45.7% compared to February 2012, but decreased by 5.2% from January 2013.

  • NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex) ADV of 4.3 million contracts in February 2013 increased 5.7% compared to February 2012 levels but decreased by 5.2% from January 2013 levels. NYSE Euronext's U.S. options exchanges accounted for 28.2% of total U.S. consolidated equity options trading in February 2013.

  • NYSE Euronext European cash products ADV of 1.5 million transactions in February 2013 decreased 9.8% compared to February 2012, but increased 12.8% compared to January 2013.

  • NYSE Euronext U.S. cash products (NYSE, NYSE Arca and NYSE MKT) handled ADV of 1.6 billion shares in February 2013 decreased 11.9% compared to February 2012 but increased 0.6% compared to January 2013. NYSE Euronext's Tape A matched market share in February 2013 was 29.4%, down from 30.0% in February 2012 and down from 29.7% in January 2013.

Please click here for the Monthly Transaction Activity Data Table.

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: http://www.nyx.com.

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS

This communication contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "may," "hope," "will," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential," "continue," "could," "future" or the negative of those terms or other words of similar meaning. You should carefully read forward-looking statements, including statements that contain these words, because they discuss our future expectations or state other "forward-looking" information. Forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. ICE and NYSE Euronext caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement.

Forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger involving ICE and NYSE Euronext, including future financial results, ICE's and NYSE Euronext's plans, objectives, expectations and intentions, the expected timing of completion of the transaction and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in ICE's and NYSE Euronext's filings with the U.S. Securities and Exchange Commission (the "SEC"). These risks and uncertainties include, without limitation, the following: the inability to close the merger in a timely manner; the inability to complete the merger due to the failure of NYSE Euronext stockholders to adopt the merger agreement or the failure of ICE stockholders to approve the issuance of ICE common stock in connection with the merger; the failure to satisfy other conditions to completion of the merger, including receipt of required regulatory and other approvals; the failure of the proposed transaction to close for any other reason; the possibility that any of the anticipated benefits of the proposed transaction will not be realized; the risk that integration of NYSE Euronext's operations with those of ICE will be materially delayed or will be more costly or difficult than expected; the challenges of integrating and retaining key employees; the effect of the announcement of the transaction on ICE's, NYSE Euronext's or the combined company's respective business relationships, operating results and business generally; the possibility that the anticipated synergies and cost savings of the merger will not be realized, or will not be realized within the expected time period; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; diversion of management's attention from ongoing business operations and opportunities; general competitive, economic, political and market conditions and fluctuations; actions taken or conditions imposed by the United States and foreign governments or regulatory authorities; and adverse outcomes of pending or threatened litigation or government investigations. In addition, you should carefully consider the risks and uncertainties and other factors that may affect future results of the combined company, as are described in the section entitled "Risk Factors" in the joint proxy statement/prospectus filed by ICE with the SEC, and as described in ICE's and NYSE Euronext's respective filings with the SEC that are available on the SEC's web site located at www.sec.gov, including the sections entitled "Risk Factors" in ICE's Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 6, 2013, and "Risk Factors" in NYSE Euronext's Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 26, 2013. You should not place undue reliance on forward-looking statements, which speak only as of the date of this written communication. Except for any obligations to disclose material information under the Federal securities laws, neither ICE nor NYSE Euronext undertakes any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this written communication.

IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND WHERE TO FIND IT

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed transaction, ICE has filed with the SEC a registration statement on Form S-4, which includes a joint proxy statement/prospectus with respect to the proposed acquisition of NYSE Euronext. The final joint proxy statement/prospectus will be delivered to the stockholders of ICE and NYSE Euronext. INVESTORS AND SECURITY HOLDERS OF BOTH ICE AND NYSE EURONEXT ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION CAREFULLY AND IN ITS ENTIRETY, INCLUDING ANY DOCUMENTS PREVIOUSLY FILED WITH THE SEC AND INCORPORATED BY REFERENCE INTO THE JOINT PROXY STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION REGARDING ICE, NYSE EURONEXT AND THE PROPOSED TRANSACTION. Investors and security holders may obtain a free copy of the joint proxy statement/prospectus, as well as other filings containing information about ICE and NYSE Euronext, without charge, at the SEC's website at http://www.sec.gov. Investors may also obtain these documents, without charge, from ICE's website at http://www.theice.com and from NYSE Euronext's website at http://www.nyx.com

PARTICIPANTS IN THE MERGER SOLICITATION

ICE, NYSE Euronext and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the Merger Agreement.

You can find information about ICE and ICE's directors and executive officers in ICE's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC on February 6, 2013, and ICE's proxy statement for its 2012 annual meeting of stockholders, as filed with the SEC on March 30, 2012.

You can find information about NYSE Euronext and NYSE Euronext's directors and executive officers in NYSE Euronext's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC on February 26, 2013, and NYSE Euronext's proxy statement for its 2012 annual meeting of stockholders, filed with the SEC on March 26, 2012.

Additional information about the interests of potential participants will be included in the joint proxy statement/prospectuses, when it becomes available, and the other relevant documents filed by ICE and NYSE Euronext with the SEC.

1 All NYSE Euronext derivatives transactions count buy and sell orders together as a single transaction. NYSE Euronext European equities transactions count each buy and sell order as separate transactions, NYSE Euronext U.S. equities transactions count buy and sell orders together as a single transaction.

NYSE Euronext

Monthly Volume Summary

Average Daily Volume

Total Volume

Average Daily Volume

Total Volume

(Unaudited; contracts in thousands)

Feb-13

Feb-12

% Chg

Feb-13

Feb-12

% Chg

YTD 2013

% Chg vs.
YTD 2012

YTD 2013

% Chg vs.
YTD 2012

Number of Trading Days - European Cash

20

21

20

21

42

42

Number of Trading Days - European Derivatives

20

21

20

21

42

42

Number of Trading Days - U.S. Markets

19

20

19

20

40

40

European Derivatives Products

4,383

2,839

54.4%

87,653

59,624

47.0%

4,636

52.8%

194,730

49.2%

of which Bclear

667

342

95.0%

14,861

7,181

107.0%

983

12.7%

37,465

95.2%

Total Fixed Income Products

2,736

1,596

71.4%

54,716

33,526

63.2%

2,889

67.7%

121,318

63.8%

Short Term Interest Rate Products

2,487

1,398

77.9%

49,742

29,364

69.4%

2,681

71.4%

112,615

67.4%

Medium and Long Term Interest Rate Products 1

249

198

25.5%

4,974

4,162

19.5%

207

31.3%

8,703

28.2%

Total Equity Products2

1,549

1,155

34.1%

30,980

24,262

27.7%

1,655

34.3%

69,498

31.2%

Individual Equity Products

1,026

745

37.7%

20,526

15,652

31.1%

1,152

39.2%

48,372

35.9%

Futures

577

214

169.2%

11,531

4,497

156.4%

689

122.3%

28,953

117.1%

Options

450

531

-15.3%

8,995

11,155

-19.4%

462

-10.7%

19,419

-12.7%

Equity Index Products

523

410

27.5%

10,453

8,610

21.4%

503

24.4%

21,126

21.5%

of which Bclear

657

342

92.0%

14,788

7,181

105.9%

981

12.4%

37,367

94.7%

Individual Equity Products

555

293

89.3%

12,745

6,153

107.1%

865

12.9%

32,492

92.8%

Futures

555

190

192.2%

11,090

3,986

178.2%

673

15.5%

28,273

120.5%

Options

-

103

1,654

2,167

-23.7%

192

4.7%

4,220

4.7%

Equity Index Products

102

49

108.7%

2,043

1,028

98.8%

116

9.1%

4,875

108.3%

Commodity Products

98

87

11.9%

1,958

1,836

6.6%

93

14.9%

3,914

12.2%

U.S. Derivatives Products

Equity Options3

NYSE Euronext Options Contracts

4,346

4,110

5.7%

82,574

82,197

0.5%

4,471

8.0%

178,837

8.0%

Total Consolidated Options Contracts

15,399

16,165

-4.7%

292,573

323,293

-9.5%

15,496

-2.6%

619,838

-2.6%

NYSE Group Share of Total

28.2%

25.4%

28.2%

25.4%

28.9%

2.9%

28.9%

2.9%

NYSE Liffe U.S.

Advertisement